ProCE Banner Activity

Dose-Expansion Results From Phase Ib/IIa CC-220-MM-001 Trial: Iberdomide + Dexamethasone in Relapsed/Refractory MM

Slideset Download
Conference Coverage
Results from dose-expansion cohort of iberdomide with dexamethasone showing clinically meaningful and durable responses in heavily pretreated R/R MM, including 97% being triple-class refractory.

Released: December 12, 2021

Expiration: December 11, 2022

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Daiichi Sankyo, Inc.

GlaxoSmithKline

Incyte Corporation

Jazz Pharmaceuticals, Inc.

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation